TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Researchers reported that levels of the enzyme UBE2N fall as fatty liver disease becomes more advanced. In mice, restoring the enzyme reduced liver fat, inflammation and scarring, but the findings are preclinical and do not establish a treatment for people.
Researchers co-led by Cedars-Sinai Health Sciences University reported that restoring the enzyme UBE2N reduced fat accumulation, inflammation and scarring in the livers of laboratory mice. The preclinical findings, published in Nature Metabolism, point to a possible way to limit progression toward more serious liver disease, but they do not show that the approach is safe or effective in people.
In the multicenter study, researchers found that UBE2N levels declined in liver cells as disease became more advanced. The team then restored the enzyme to normal levels in the livers of laboratory mice. They observed reductions in fat accumulation, inflammation and scarring, features associated with the more severe disease form known as MASH.
The authors link UBE2N to the handling of damaged mitochondria, the cell structures that produce energy, and to the breakdown of fat. Ekihiro Seki, a Cedars-Sinai professor of medicine and biomedical sciences and a co-corresponding author, said the enzyme appeared to protect against inflammation and liver damage by helping remove damaged mitochondria and supporting fat breakdown. He said lower enzyme levels were accompanied by more damaged cells and liver injury.
The researchers said the findings could make UBE2N a potential treatment target for preventing MASLD from advancing to MASH. The experiment tested enzyme restoration in mice; it did not establish a therapy, determine how an intervention might be delivered to patients, or show whether the same results occur in humans.
A Possible Route to Limit Liver Injury
The findings address a gap in treatment for metabolic dysfunction-associated steatohepatitis (MASH), a more serious form of fatty liver disease involving excess fat alongside inflammation, cell injury and scarring. According to the source report, care mainly focuses on lifestyle changes and limiting further liver damage. Medication options remain limited, and there is currently no cure for MASH.
The American Liver Foundation estimates that about 100 million people in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD). Roughly 20% to 25% of people affected go on to develop MASH, according to the report. A strategy that could slow worsening disease would be relevant to a large population, but the mouse results offer an early biological lead, not evidence that patients would benefit.
UBE2N may also help researchers understand how mitochondrial damage relates to disease progression. If later studies confirm that this pathway can be safely influenced in people, it could potentially complement existing care. The study does not yet show whether increasing the enzyme would improve health outcomes, prevent liver failure, or work alongside current treatments.
As an affiliate, we earn on qualifying purchases.
From MASLD to More Severe MASH
MASLD is the current name for a condition previously called nonalcoholic fatty liver disease. In some people, the disease progresses to MASH, where liver fat is accompanied by inflammation and tissue damage. Scarring can develop as the injury continues. The source report describes MASH as a more serious stage, while noting that researchers are still working to understand why some people progress.
Earlier research had suggested that damaged mitochondria may contribute to MASH development and progression. The new study builds on that line of inquiry by connecting declining UBE2N levels with more advanced disease and testing what happened when levels were restored in mice. The work was supported by several research funders, including the U.S. National Institutes of Health, South Korean research programs and the National Natural Science Foundation of China.
““When levels of the enzyme fell, we saw more damaged cells and injury to the liver.””
— Ekihiro Seki, MD, PhD
As an affiliate, we earn on qualifying purchases.
Human Benefits Remain Unproven
The reported results come from laboratory mice, and the source material does not report a clinical trial in people. It is not yet clear whether UBE2N levels change in the same way across different patients, whether increasing the enzyme could be done safely, or what dose and delivery method might be needed.
The study also does not establish whether UBE2N restoration can reverse existing liver damage, prevent progression over the long term, or reduce the risk of liver failure. Those outcomes would require further research. The report does not specify a timeline for studies in people or describe a treatment ready for clinical use.
As an affiliate, we earn on qualifying purchases.
Studies Must Test the Pathway
The researchers say future work can test whether enhancing the UBE2N pathway might complement existing treatments and identify patients most likely to benefit. Further studies would need to establish how the pathway operates in human disease and assess the safety and effects of any proposed intervention before patient trials could show whether it improves outcomes.
For now, the result is a research finding in mice. The next meaningful milestone would be evidence that the protective effect holds in additional studies and can be translated safely into human research. No clinical availability or trial schedule is specified in the source report.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is UBE2N?
UBE2N is an enzyme that the researchers linked to the removal of damaged mitochondria and the breakdown of fat in the liver. The study found that its levels fell as liver disease became more advanced.
Did restoring UBE2N help people with fatty liver disease?
The reported experiment was conducted in laboratory mice. It does not show whether restoring UBE2N helps people, and the source report does not describe a human trial.
What changed in the mice?
After researchers restored UBE2N to normal levels in the mice’s livers, they observed less fat accumulation, inflammation and scarring. The report does not establish the long-term effects of the intervention.
Is UBE2N a treatment for MASH now?
No treatment based on UBE2N is established by this study. The researchers describe the enzyme as a potential treatment target, and further studies would be needed before its relevance to patient care is known.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
